Summit Therapeutics (SMMT) reported a Q4 non-GAAP net loss Monday of $0.07 per diluted share, widening from a loss of $0.04 a year earlier.
Analysts polled by FactSet expected a loss of $0.08.
The biopharmaceutical company did not report any revenue.
The company reported cash, cash equivalents and short-term investments of $412.3 million as of Dec. 31, up from $186.2 million a year earlier.
Summit shares were up nearly 11% in recent premarket activity
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。